| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions
|
Claxton, Karl
|
|
2016
|
19 |
6 |
p. 885-891
7 p.
|
artikel
|
| 2 |
Adherence to Self-Care Behaviors among Patients with Type 2 Diabetes—The Role of Risk Preferences
|
Simon-Tuval, Tzahit
|
|
2016
|
19 |
6 |
p. 844-851
8 p.
|
artikel
|
| 3 |
A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies
|
Ho, Martin
|
|
2016
|
19 |
6 |
p. 746-750
5 p.
|
artikel
|
| 4 |
A Systematic Review of Health Economic Evaluation Studies Using the Patient’s Perspective
|
Tai, Bik-Wai Bilvick
|
|
2016
|
19 |
6 |
p. 903-908
6 p.
|
artikel
|
| 5 |
Attribute Development Using Continuous Stakeholder Engagement to Prioritize Treatment Decisions: A Framework for Patient-Centered Research
|
dosReis, Susan
|
|
2016
|
19 |
6 |
p. 758-766
9 p.
|
artikel
|
| 6 |
Comparison of Daily versus Weekly Recording of Gastroesophageal Reflux Disease Symptoms in Patients with a Partial Response to Proton Pump Inhibitor Therapy
|
Rydén, Anna
|
|
2016
|
19 |
6 |
p. 829-833
5 p.
|
artikel
|
| 7 |
Copyright/Subscription
|
|
|
2016
|
19 |
6 |
p. iv-
1 p.
|
artikel
|
| 8 |
Cost-Effectiveness of Rotavirus Vaccination in France—Accounting for Indirect Protection
|
Yamin, Dan
|
|
2016
|
19 |
6 |
p. 811-819
9 p.
|
artikel
|
| 9 |
Decision Modeling for Cost-Utility Analysis
|
Kuntz, Karen M.
|
|
2016
|
19 |
6 |
p. 700-701
2 p.
|
artikel
|
| 10 |
Developing a Patient-Centered Benefit-Risk Survey: A Community-Engaged Process
|
Hollin, Ilene L.
|
|
2016
|
19 |
6 |
p. 751-757
7 p.
|
artikel
|
| 11 |
Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database
|
Schulman, Kathy L.
|
|
2016
|
19 |
6 |
p. 852-860
9 p.
|
artikel
|
| 12 |
Did It Matter That the Cancer Drugs Fund Was Not NICE? A Retrospective Review
|
Dixon, Padraig
|
|
2016
|
19 |
6 |
p. 879-884
6 p.
|
artikel
|
| 13 |
Economic Impact of Integrated Care Models for Patients with Chronic Diseases: A Systematic Review
|
Desmedt, Melissa
|
|
2016
|
19 |
6 |
p. 892-902
11 p.
|
artikel
|
| 14 |
Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report
|
Wolowacz, Sorrel E.
|
|
2016
|
19 |
6 |
p. 704-719
16 p.
|
artikel
|
| 15 |
Financing a Cure for Diabetes in a Multipayer Environment
|
Basu, Anirban
|
|
2016
|
19 |
6 |
p. 861-868
8 p.
|
artikel
|
| 16 |
First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment
|
Mühlbacher, Axel
|
|
2016
|
19 |
6 |
p. 776-787
12 p.
|
artikel
|
| 17 |
From the Co-Editors-In-Chief
|
|
|
2016
|
19 |
6 |
p. 699-
1 p.
|
artikel
|
| 18 |
Impact of Treatment Subsidies and Cash Payouts on Treatment Choices at the End of Life
|
Finkelstein, Eric
|
|
2016
|
19 |
6 |
p. 788-794
7 p.
|
artikel
|
| 19 |
Increasing Patient Involvement in Drug Development
|
Lowe, Maria M.
|
|
2016
|
19 |
6 |
p. 869-878
10 p.
|
artikel
|
| 20 |
Instructions for Authors
|
|
|
2016
|
19 |
6 |
p. I-IV
nvt p.
|
artikel
|
| 21 |
International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory Decisions
|
Reed, Shelby D.
|
|
2016
|
19 |
6 |
p. 727-729
3 p.
|
artikel
|
| 22 |
Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L
|
Goranitis, Ilias
|
|
2016
|
19 |
6 |
p. 820-828
9 p.
|
artikel
|
| 23 |
Measuring High-Risk Patients’ Preferences for Pharmacogenetic Testing to Reduce Severe Adverse Drug Reaction: A Discrete Choice Experiment
|
Dong, Di
|
|
2016
|
19 |
6 |
p. 767-775
9 p.
|
artikel
|
| 24 |
Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions: The European Union Perspective
|
Mühlbacher, Axel C.
|
|
2016
|
19 |
6 |
p. 734-740
7 p.
|
artikel
|
| 25 |
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
|
Hoogendoorn, Martine
|
|
2016
|
19 |
6 |
p. 800-810
11 p.
|
artikel
|
| 26 |
Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective
|
Johnson, F. Reed
|
|
2016
|
19 |
6 |
p. 741-745
5 p.
|
artikel
|
| 27 |
Regulatory Decision Making in Canada—Exploring New Frontiers in Patient Involvement
|
Klein, Agnes V.
|
|
2016
|
19 |
6 |
p. 730-733
4 p.
|
artikel
|
| 28 |
Response to Editorial: Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report
|
|
|
2016
|
19 |
6 |
p. 702-703
2 p.
|
artikel
|
| 29 |
Table of Contents
|
|
|
2016
|
19 |
6 |
p. i-iii
nvt p.
|
artikel
|
| 30 |
The Capability Approach: A Critical Review of Its Application in Health Economics
|
Karimi, Milad
|
|
2016
|
19 |
6 |
p. 795-799
5 p.
|
artikel
|
| 31 |
When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices
|
Grimm, Sabine E.
|
|
2016
|
19 |
6 |
p. 720-726
7 p.
|
artikel
|
| 32 |
Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30
|
van Dongen-Leunis, Annemieke
|
|
2016
|
19 |
6 |
p. 834-843
10 p.
|
artikel
|
Tijdschrift beschrijving